Category: Sanofi

PRESS RELEASE Published June 9, 2023 The Latest Research Report on Fanconi Anemia Market 2023 covering the micro level of analysis by competitors and key business segments. The Global Fanconi Anemia explores an inclusive study on various segments like growth drivers, opportunities, market size, shares, development, innovation, sales, and overall…

PRESS RELEASE Published June 8, 2023 Biotechnology is the application of scientific and engineering principles to the processing of materials by biological agents to provide goods and services. Today, biotechnology is being used to create new and improved crop varieties, develop renewable fuels, and create new industrial and consumer products….

Funding Support and Acknowledgements: COPDGene: The project described was supported by Award Number U01 HL089897 and Award Number U01 HL089856 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung,…

Superior global cognition in the oldest-old was associated with resistance to neurodegenerative pathologies, autopsy data showed. (Journal of Alzheimer’s Disease) Brain network models showed that people with higher intelligence scores took more time to solve difficult problems, and that slower solvers had higher average functional connectivity. (Nature Communications) The novel…

BNT316/ONC-392 is a next-generation anti-CTLA-4 monoclonal antibody candidate jointly developed by BioNTech and OncoC4 as monotherapy or combination therapy in a range of solid tumor indications, including non-small cell lung cancer (NSCLC) Interim data of BNT316/ONC-392 from the ongoing Phase 1/2 trial to be presented at this year’s…

MANNHEIM, Germany — A novel drug that targets production of a liver protein involved in lipid metabolism appears to markedly reduce low-density lipoprotein (LDL) cholesterol levels for patients with homozygous familial hypercholesterolemia (HoFH), suggest results from the phase 2 GATEWAY trial. The research was presented at the European Atherosclerosis Society…

Sobi® will present data at the EHA (European Haematology Association) hybrid congress taking place in Frankfurt, Germany 8-11 June, 2023, highlighting the company’s commitment in rare haematological diseases. During the congress, Sobi will present important new data on haemophilia, immune thrombocytopenia, relapsed or refractory diffuse large b-cell lymphoma (DLBCL), and…

New data, being presented in a late-breaking session at the 2023 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, demonstrate that frexalimab, Sanofi’s novel second-generation investigational anti-CD40L antibody, with a unique mechanism of action, significantly reduced disease activity in a phase 2 trial of patients with relapsing multiple sclerosis (MS). …

RNA-targeted NBTs that are currently being used to upregulate gene expression address both transcriptional and translational mechanisms and can be roughly divided into two groups: (1) NBTs that increase mRNA abundance by enhancing transcription or increasing mRNA stability (Fig. 3) and (2) NBTs that optimize translation (Fig. 4). Strategies in the first…

Positive results in a late-stage clinical trial put Pfizer’s marstacimab in a position to become the first weekly injectable for patients with hemophilia B, the drugmaker said Tuesday.  If approved, the monoclonal antibody would also pose fresh competition to Roche and Sanofi in hemophilia A, although to what extent is…

PRESS RELEASE Published May 24, 2023 DelveInsight’s, “NK Cell Therapy Pipeline Insight 2023” report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in the NK Cell Therapy pipeline landscape. It covers the NK Cell Therapy pipeline drug profiles, including NK Cell Therapy clinical trials and nonclinical stage products….

PRESS RELEASE Published May 24, 2023 “Global Gene Therapy for Blood Disorders Market Trends, Industry Competition Analysis, Revenue and Forecast To 2031.” Request for Sample Pages: www.insightaceanalytic.com/request-sample/1156 According to the latest research by InsightAce Analytic, the global gene therapy for blood disorders market is expected to growwith a CAGR of…

Global Biotechnology Market Size & Share to Surpass $2772.7 Billion by 2030 | Vantage Market Research WASHINGTON, May 22, 2023 (GLOBE NEWSWIRE) — The Global Biotechnology Market is valued at USD 1094.6 Billion in 2022 and is projected to reach a value of USD 2772.7 Billion by 2030 at a…

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new results from an interim analysis of exploratory data from the open-label extension (OLE) period of the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy….

(RTTNews) – Sanofi and Regeneron Pharmaceuticals Inc. (REGN) presented positive Phase 3 results evaluating the investigational use of Dupixent (dupilumab) compared to placebo in adults currently on maximal standard-of-care inhaled therapy (triple therapy) with uncontrolled chronic obstructive pulmonary disease or COPD and evidence of type 2 inflammation. The Dupixent Phase…

– Continued Treatment with Patisiran in Open-Label Extension Period Showed Evidence of Sustained Benefit across Measures of Functional Capacity and Health Status and Quality of Life, as well as Cardiac Stress and Injury, through 18 Months – – Safety Profile Consistent with that Observed in 12-Month Double-Blind Period, with No…

– Continued Treatment with Patisiran in Open-Label Extension Period Showed Evidence of Sustained Benefit across Measures of Functional Capacity and Health Status and Quality of Life, as well as Cardiac Stress and Injury, through 18 Months – – Safety Profile Consistent with that Observed in 12-Month Double-Blind Period, with No…

PRESS RELEASE Published May 19, 2023 The global progressive familial intrahepatic cholestasis type 2 treatment market size was valued at USD 35 million in 2021 and is projected to reach around USD 550 million in 2030 exhibiting a CAGR of 39.0% in the forecasted period.  Introduction The Global Progressive Familial…

Roche Holdings AG’s  (OTC: RHHBY) Phase 2 FENopta study of oral fenebrutinib for relapsing forms of multiple sclerosis (RMS) met its primary and secondary endpoints. The data showed oral fenebrutinib significantly reduced magnetic resonance imaging (MRI) markers of MS disease activity in the brain compared to placebo. Additionally, pre-clinical data have shown fenebrutinib…

The story so far: Dengue is the world’s fastest-growing vector borne disease: evidence shows over the past 50 years, there was a 30-50-fold increase in dengue cases in tropical and subtropical countries, like India. While dengue is largely accepted as an annual epidemic in several countries (impacting more than 3.6…

Pictured: Illustration of CRISPR-Cas9 editing DNA / iStock, Artur Plawgo Tuesday, Jennifer Doudna-founded Scribe Therapeutics and Eli Lilly subsidiary Prevail entered into a strategic collaboration to develop CRISPR-based genetic medicines for neurological and neuromuscular indications. Under the terms of the agreement, Prevail will make a $75 million upfront payment and equity…

Scribe Therapeutics Inc., a company creating genetic medicines through its CRISPR by Design approach to genetic modification, has announced a strategic collaboration with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company. The deal gives Prevail exclusive rights to Scribe’s CRISPR X-Editing (XE) technologies for the development of…

Benjamin L. Oakes, PhD, Scribe Therapeutics co-founder, president, and CEO Scribe Therapeutics will partner with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly, to develop in vivo CRISPR-based therapies for “serious” neurological and neuromuscular diseases, the companies said today, through a collaboration that could generate more than $1.5 billion…

Sarclisa (isatuximab), given on top of standard treatment with Kyprolis (carfilzomib) and the steroid dexamethasone, was found to delay disease progression by almost three years, on average, in people with relapsed or refractory — hard-to-treat — multiple myeloma, according to updated data from a Phase 3 clinical trial. These results corresponded…

MT Newswires 2023 Analyst Recommendations on SANOFI Sales 2023 44 296 M 48 106 M 48 106 M Net income 2023 8 088 M 8 784 M 8 784 M Net Debt 2023 5 289 M 5 744 M 5 744 M P/E ratio 2023 15,4x Yield 2023 3,71% Capitalization 124 B 135 B…

The sellside expects a bumper year for blockbuster approvals, a recent Evaluate Vantage analysis revealed, but which products are creating all the excitement? A handful of significant new agents have already been approved, in Alzheimer’s disease, geographic atrophy and respiratory syncytial virus, and there is no shortage of pending regulatory…

PRESS RELEASE Published May 11, 2023 Biotechnology is the application of scientific and engineering principles to the processing of materials by biological agents to provide goods and services. Today, biotechnology is being used to create new and improved crop varieties, develop renewable fuels, and create new industrial and consumer products….

WEDNESDAY, May 10, 2023 (HealthDay News) — For adults with prurigo nodularis (PN), dupilumab, a fully human monoclonal antibody that blocks the shared receptor component for interleukin (IL)-4 and IL-13, demonstrates clinically meaningful and significant improvements in itch and skin lesions in two phase 3 trials (LIBERTY-PN PRIME and PRIME2),…

Sanofi and Regeneron’s Dupixent (dupilumab) was associated with significant improvements in uncontrolled prurigo nodularis symptoms, according to positive phase 3 results recently published in Nature Medicine. Prurigo nodularis is a chronic, debilitating skin disease with underlying type 2 inflammation and its impact on quality of life is, as reported by…

  Drugs that can be purchased over-the-counter do not require a prescription. Aches, pains, and itches can be treated with some OTC medications. Some treat or prevent conditions including athlete’s foot and tooth rot. Other over-the-counter medicines could assist in managing chronic conditions including allergies and migraines. When used as…

The global CRISPR Nucleases Market research report gives point to point breakdown along with the data of CRISPR Nucleases market analytical study, regional analysis, growth factors and leading companies. The research report about the market provides the data about the aspects which drive the expansion of industry. The CRISPR Nucleases…

ROCKVILLE, MD. and SUZHOU, China, May 8, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that the first patient with Thyroid Eye Disease (TED) has…

Yahoo Finance published this video item, entitled “Why the human genome could be health care’s holy grail” – below is their description. #youtube #stockmarket #genetics 23andMe Co-founder & CEO Anne Wojcicki says we’ve only seen the tip of the iceberg for human genomics and DNA research. “Look at all the…

Small Interfering RNA (SiRNA) Market is projected to reach USD 964.17 Million by 2030 : Cognitive Market Research Market Overview: – Small interfering RNA (siRNA) is a class of double-stranded RNA operating within the RNA interference (RNAi) pathway. They exert their effects by RNA interference (RNAi) of their target mRNA….

The “wildtype” RNA sequence contains numerous unpaired nucleotide loops, which leads to less stability. The LinearDesign algorithm generates sequences with significantly fewer loops, a more stable structure. Credit: Baidu Research A team of researchers from Baidu Research has developed an AI algorithm that can rapidly design highly stable COVID-19 mRNA…

PRESS RELEASE Published April 28, 2023 DelveInsight’s, “Autosomal dominant polycystic kidney disease Pipeline Insight 2023” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Autosomal dominant polycystic kidney disease pipeline landscape. It covers the Autosomal dominant polycystic kidney disease pipeline drug profiles, including Autosomal dominant polycystic kidney…

Schroder UK Public Private Trust might be in the process of changing its name, but it’s still struggling to distance itself from Neil Woodford. The trust, previously Woodford Patient Capital Trust and soon to be renamed Schroder Capital Global Innovation, has had another tough year. In its latest results, Schroder…

Biologics accounted for more new drug approvals than did small molecules for the first time in 2022, marking a significant shift in the pharmaceutical industry (1). Large-molecule pipelines are also moving from standard monoclonal antibodies (MAbs) to more complex and difficult-to-express molecules, which intensifies pressure on the industry to meet…

Swedish researchers have developed a microfluidic chip that they hope will allow for easier monitoring of monoclonal antibody (mAb) production. The protein cartridge, developed by a team from KTH Royal Institute of Technology in Stockholm, allows for the simultaneous analysis of up to four different proteins in the cell culture…

Patients with unresectable metastatic desmoplastic melanoma, a rare amelonotic subtype of cutaneous melanoma, achieved high response rates when treated with single-agent pembrolizumab (Keytruda) in the SWOG S1512 trial (NCT02775851), according to data presented during the 2023 AACR Annual Meeting.1 “Based on these data, single-agent, anti-PD1 immunotherapy should be considered the…

ROCKVILLE, Md. and SUZHOU, China, April 17, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announced the final analysis results of ORIENT-16, the Phase 3…

ROCKVILLE, Md. and SUZHOU, China, April 16, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announced that the final analysis results of ORIENT-15, the Phase…

ROCKVILLE, Md. and SUZHOU, China , April 17, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announced the final analysis results of ORIENT-16, the Phase…

ROCKVILLE, Md. and SUZHOU, China, April 16, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announced that the final analysis results of ORIENT-15, the Phase…

PRESS RELEASE Published April 15, 2023 InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Gene Therapy for Blood Disorders Market Trends, Industry Competition Analysis, Revenue and Forecast To 2030.” Get Free Sample Copy of Report : www.insightaceanalytic.com/request-sample/1156 According to the latest research by…

Merck KGaA has said that the US Food and Drug Administration (FDA) has placed a partial clinical hold on new patients receiving its multiple sclerosis (MS) drug candidate evobrutinib. The hold specifically applies to patients who have been taking the drug for less than 70 days, the company said, adding…

Because of safety concerns, the FDA has placed a partial clinical hold on the initiation of evobrutinib (EMD Serono), an investigational Bruton’s tyrosine kinase (BTK) inhibitor, in new patients and those with less than 70 days of exposure. EMD Serono noted that this decision does not impact the status of…

doi: 10.1016/j.nantod.2022.101665. Epub 2022 Nov 7. Affiliations Expand Affiliations 1 Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran 1449614535, Iran. 2 Department of Medical Nanotechnology, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran 1449614535, Iran. 3 Laser Research Centre, Faculty of Health Science,…

Competing interests A.R. is a founder, equity owner, and consultant at Halo Solutions and has served as a consultant at Tyra Biosciences. J.F.G. has served as a compensated consultant or received honoraria from Bristol Myers Squibb, Genentech/Roche, Ariad/Takeda, Loxo/Lilly, Blueprint, Oncorus, Regeneron, Gilead, Moderna, Mirati, AstraZeneca, Pfizer, Novartis, iTeos, Nuvalent,…

Your new post is loading… Your new post is loading… Scooped by Ed Rybicki Scoop.it! Scooped by Ed Rybicki Scoop.it! This study has helped elucidate the responses underlying susceptibility to H5N1 influenza in avian species, which will be critical in developing sustainable strategies for future control of HPAI in domestic…

Pornpak Khunatorn Lyra Therapeutics – Overview Lyra Therapeutics (NASDAQ:LYRA) (the Company), a Massachusetts drug/device combination company trading on the NASDAQ, is developed two forms of a proprietary elastomeric drug-eluting matrix for chronic rhinosinusitis (CRS) patients who fail normal medical management of their condition. The Company’s product can be inserted into…

Dupixent (dupilumab) — a medication initially approved for exzema — was found to significantly reduce the number of disease exacerbations and to improve lung function in people with chronic obstructive pulmonary disease (COPD), meeting the primary and key secondary goals of the pivotal Phase 3 BOREAS trial. A similarly designed…

Two fitusiran Phase 3 studies published in The Lancet and The Lancet Haematology highlight potential to address unmet needs across all types of hemophilia Both Phase 3 studies achieved their primary and secondary endpoints; fitusiran prophylaxis demonstrated significant and clinically meaningful improvements in bleed protection across all hemophilia populations,…

BIO-Europe Spring is one of Europe’s biggest biotech partnering events with discussion topics ranging from platform technologies and manufacturing to biotech investments. Here are some of the key take-home reports from the proceedings. The event, which took place from March 20 to 22, in the budding biotech hub of Basel,…

In adults with uncontrolled chronic obstructive pulmonary disease (COPD) and evidence of type 2 inflammation, the biologic agent dupilumab was associated with a 30% reduction in disease exacerbations compared to placebo as well as with rapid and significant improvement in lung function, quality of life (QoL) and COPD respiratory symptoms….

News All EMBL-EBI news collaboration Using drug screens and CRISPR to make better cancer drugs 6 July 2020 EUbOPEN consortium will provide tools to unlock disease biology 5 June 2020 B cells linked to immunotherapy for melanoma 12 September 2019 BioImage Archive – a new hub for biological images 2…

ROCKVILLE, Md. and SUZHOU, China, March 21, 2023  /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, today announced that clinical data from multiple trials in relation to…

This article was updated by Willow Shah-Neville on March 20, 2023. The question of whether to partner with another company is critical to the long-term development of a biotech. Nonetheless, it can be easy for a small company to underestimate the resources it needs to put into a successful collaboration….

March 19, 2023 2 min read Source/Disclosures Published by: Source: Simpson E. Dupilumab treatment in patients with hand and foot atopic dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial. Presented at: American Academy of Dermatology Annual Meeting; March 17-21, 2023; New Orleans. Disclosures: Eichenfield reports…

Michael A. Carducci, MD, professor of oncology, AEGON Professor of Prostate Cancer Research, Johns Hopkins Medicine, discusses the significance of two ongoing clinical trials in prostate cancer: the phase 3 CAPItello-280 trial (NCT05348577) and phase 3 INDICATE study (EA8191; NCT04423211). The randomized CAPItello-280 trial was designed to build on preclinical…

ADC Therapeutics SA 2022 Annual Report Table of Contents Letter to Shareholders Business Update Financial Review Corporate Governance Report from the Auditor on the Consolidated IFRS Financial Statements Consolidated IFRS Financial Statements for the Year Ended December 31, 2022 Report from the Auditor on the Statutory Financial Statements of ADC…

CE Activity Release Date: March 15, 2023CE Activity Expiration Date: February 28, 2024 Time to Complete activity: 1 hour ACTIVITY DESCRIPTION Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, which typically occurs in patients over the age of 60 years. While chemoimmunotherapy (R-CHOP) has been…

The Human DNA Vaccines Market report signifies gathered information about a market within an industry or various industries. The Human DNA Vaccines Market report includes analysis in terms of both quantitative and qualitative data with a forecast period of the report covering from 2023 to 2030. The report is prepared…

The market report is a good combination of qualitative and quantitative data that highlights significant market changes, obstacles that business and the competition must overcome, as well as new possibilities and trends in the Recombinant DNA Technology Market. JERSEY CITY, N.J. , March 13, 2023 /PRNewswire/ — The global Recombinant DNA…

Sanofi and Provention Bio, Inc., a U.S.-based, publicly traded biopharmaceutical company focused on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D), have entered into an agreement under which Sanofi has agreed to acquire Provention Bio, Inc., for $25.00 per share in cash, representing an equity value of approximately…

Also find out how he got rich at the age of 58. Larry Weiss is the Chief Legal Officer and Corporate Secretary at Butterfly Network, Inc. where he oversees and is responsible for all legal and compliance matters. Net Worth: $200 Million. Our excitement for Ion Torrent remains stronger than…

Jing Dong is supported by the Medical College of Wisconsin Cancer Center. N00014-17-1-2850 from the Office of Naval Research. The CIBMTR is supported primarily by Public Health Service U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and…

Editas Medicine, Inc. Linea Aspesi Linea Aspesi, Executive Vice President and Chief People Officer, Editas Medicine CAMBRIDGE, Mass., March 08, 2023 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Linea Aspesi as the Company’s Executive Vice President and Chief People…

Abstract Diffuse large B-cell lymphoma (DLBCL) is cured in over 60% of patients, but outcomes are poor for patients with relapsed or refractory disease (rrDLBCL). Here, we performed whole genome/exome sequencing (WGS/WES) on tumors from 73 serially-biopsied patients with rrDLBCL. Based on the observation that outcomes to salvage therapy/autologous stem…

MIAMI BEACH — As cases of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) continue to emerge, clinical experience has shown that the disease is heterogeneous and that multidisciplinary treatment provides the best outcomes, said a breast surgeon here. By the end of 2022, the American Society of Plastic Surgeons’ global…

MIAMI BEACH — As more cases of breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) emerge, clinical experience has shown the disease to be heterogeneous and that multidisciplinary management provides the best results, a breast surgeon said here. As of late 2022, the American Society of Plastic Surgeons global tracking network had…

Summary Background In the KEYNOTE-826 study, the addition of the anti-PD-1 monoclonal antibody pembrolizumab to chemotherapy with or without bevacizumab improved overall survival and progression-free survival (primary endpoints) versus placebo plus chemotherapy with or without bevacizumab, with manageable toxicity, in patients with persistent, recurrent, or metastatic cervical cancer. In this…

Most children with hemophilia A given Altuviiio (efanesoctocog alfa) once a week were bleed-free throughout about a year of treatment. That’s according to top-line data from the Phase 3 XTEND-Kids trial (NCT04759131) announced by Sobi and Sanofi, the therapy’s co-developers, less than a month after the U.S. Food and Drug Administration (FDA)…

Abstract The human gut microbiome composition has been linked to Parkinson’s disease (PD). However, knowledge of the gut microbiota on the genome level is still limited. Here we performed deep metagenomic sequencing and binning to build metagenome-assembled genomes (MAG) from 136 human fecal microbiomes (68 PD samples and 68 control…

Completed XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIO™ to redefine expectations for treatment of children <12 years of age with hemophilia A Paris, March 2, 2023. The XTEND-Kids phase 3 pivotal study evaluating the safety, efficacy and pharmacokinetics of ALTUVIIIO as once-weekly prophylaxis in previously treated patients <12 years…

PARIS, March 2 (Reuters) – A phase-3 study on the safety and efficacy of its ALTUVIIIO Hemophilia A treatment used for children met its primary endpoint, the French drugmaker said on Thursday. “The completion of XTEND-Kids represents the final milestone needed for regulatory submission in the EU,” Sanofi said in…

Results Patients in ELEVATE UC 52 were enrolled between June 13, 2019, and Jan 28, 2021. Patients in ELEVATE UC 12 were enrolled between Sept 15, 2020, and Aug 12, 2021. ELEVATE UC 52 and ELEVATE UC 12 screened 821 patients and 606 patients, respectively, with 433 and 354 subsequently…

(RTTNews) – Sanofi – Aventis Groupe said Thursday that the XTEND-Kids phase 3 pivotal study, which evaluated the safety, efficacy and pharmacokinetics of Altuviiio as once-weekly prophylaxis in previously treated patients less than 12 years of age with severe hemophilia A, met its primary endpoint of safety, with no FVIII…

By Varvara Melikhova, founder and CEO of Unison Innovations Strategic partnerships are a better way to build a product’s capabilities than outright acquisitions. While the M&A path is set out for the most mature successful startups, early-stage partnerships can enhance a product’s market value and provide access to Big Pharma…

Developing an effective vaccine against dengue is tricky because it is caused by four closely related viruses called serotypes; an ideal vaccine must target all four Illustration: Yogendra Anand / CSE In a significant development in DNA vaccination research, India’s first and only DNA vaccine candidate for dengue has shown promising…

According to Precision Business Insights’ (PBI), latest report, the Europe bruton tyrosine kinase (btk) inhibitors market size was valued at USD 1,911.3 million in 2021 and is poised to grow at a significant CAGR of 21.3% during the forecast period 2022-28. The Europe Bruton Tyrosine Kinase (BTK) Inhibitors Market is…

The U.S. Food and Drug Administration (FDA) has approved ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], previously referred to as efanesoctocog alfa, a first-in-class, high-sustained factor VIII replacement therapy.  ALTUVIIIO is indicated for routine prophylaxis and on-demand treatment to control bleeding episodes, as well as perioperative management (surgery) for adults…

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Gene Therapy for Blood Disorders Market Trends, Industry Competition Analysis, Revenue and Forecast To 2030.” Request for Sample Pages:According to the latest research by InsightAce Analytic, the global gene therapy for blood disorders market is…

NEWARK, Del, Feb. 20, 2023 (GLOBE NEWSWIRE) — During the forecast period 2023 to 2033, the Castration-Resistant Prostate Cancer (CRPC) Treatment Market is expected to grow at a value of 9.5% CAGR, according to Future Market Insights. By the year 2033, the global market for Castration-Resistant Prostate Cancer (CRPC) Treatment…

. 2023 Jan-Dec;15(1):2175311. doi: 10.1080/19420862.2023.2175311. Affiliations Expand Affiliations 1 CEA, INRAE, Medicines and Healthcare Technologies Department, Université Paris-Saclay, SIMoS, France. 2 Sanofi, Large Molecule Research, Vitry-sur-Seine, France. 3 Sanofi, Integrated Drug Discovery, Vitry-sur-Seine, France. Item in Clipboard Tiphanie Pruvost et al. MAbs. 2023 Jan-Dec. Show details Display options Display options Format…

Avilar Therapeutics has raised additional funding with an expanded syndicate of new investors to support advancing a pipeline of first-in-class extracellular protein degraders.  The new financing takes the company’s total to $75 million. The seed round had initial funding from Avilar’s founding investor, RA Capital Management, and now includes participation…

Innovent Announces First Patient Dosed in a Phase 3 Clinical Trial (CLEAR) of Picankibart (Anti-IL23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Plaque Psoriasis Details Category: Antibodies Published on Thursday, 16 February 2023 11:15 Hits: 271 ROCKVILLE, MD, USA and SUZHOU, China I February 15, 2023 I Innovent Biologics, Group. (“Innovent”)…

ROCKVILLE, Md. and SUZHOU, China, Feb. 15, 2023 /PRNewswire/ — Innovent Biologics, Group. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announced that the first patient with moderate-to-severe plaque psoriasis has…

In the recently published phase 3 Antelope trial (NCT04115488), biosimilar natalizumab (biosim-NTZ), or PB006, the first biosimilar monoclonal antibody developed for multiple sclerosis (MS), matched reference natalizumab (ref-NTZ; Tyasbri; Biogen) in efficacy, safety, and immunogenicity in treating patients with relapsing-remitting MS (RRMS). After 24 weeks of treatment, the model-based mean…

Sanofi is stopping the clinical development of tolebrutinib for treating myasthenia gravis (MG), the company announced in a recent press release. The decision was made after “careful evaluation of the emerging competitive treatment landscape in MG,” according to Sanofi, and will result in discontinuing the Phase 3 URSA trial (NCT05132569),…

PRESS RELEASE Published February 2, 2023 Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, about 50+ key pharma and biotech companies are working on 50+ pipeline drugs in the Systemic Sclerosis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types….

Plasmids are an important starting material for the manufacturing of mRNA- and cell-based drugs The new plasmid manufacturing facility aims to increase BioNTech’s autonomy and flexibility in manufacturing an important starting material for its oncology and COVID-19 vaccine pipeline The investment of approximately €40 million is part…

The U.S. Food and Drug Administration (FDA) has approved an expansion of the indication for Enjaymo (sutimlimab-jome) to include cold agglutinin disease (CAD) patients without a history of blood transfusions. The therapy was first approved by the FDA nearly a year ago for patients who had previously received blood transfusions….

The newly published report titled “Global Gene Therapy for Blood Disorders Market- By Trends, Industry Competition Analysis, Pipeline Analysis/Clinical Trial, Revenue (US$ Billions) and Forecast Till 2030.” features in-depth analysis and an extensive market study, exploring its significant upcoming years industry factors. According to the latest gene therapy industry market…

Press Release: NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating its potential to transform the treatment landscape for people with hemophilia A NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating its potential to transform the treatment landscape for people with hemophilia A P aris and Stockholm – January…

In a recent special communication report published in JAMA Network Open, researchers described the coronavirus disease 2019 (COVID-19) prevention network (CoVPN) and its contribution to clinical efficacy evaluations of COVID-19 vaccines in phase 3 trials. Study: Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials….

image: Leif S. Ludwig receives the Paul Ehrlich and Ludwig Darmstaedter Early Career Award. view more  Credit: Thomas Rafalzyk, Berlin Institute of Health FRANKFURT. Our blood renews itself constantly. Each second, millions of new cells are added to our bloodstream which replace dying blood cells. They originate from haematopoietic (blood-forming) stem…

AstraZeneca kicked off this year’s J.P.Morgan Healthcare Conference in style, announcing a $1.8 billion deal that gave it ownership of CinCor Pharma and its mid-phase hypertension drug baxdrostat. But while Fierce Biotech reported at the time that AstraZeneca was able to exploit CinCor’s deflated share price, that was only part…

Thanks to a breakthrough in biotechnology made by two Nobel Prize-winning researchers in 2020, it will soon be possible to treat genetic diseases and cancer through selective gene sharing. The innovative method CRISPR/Cas9 it has also aroused interest among investors, thanks to which both Nobel laureates were able to create…

About the job Our Team: Artificial Intelligence (AI) and Machine Learning (ML) algorithms can significantly speed up drug discovery and shorten drug development and identification of patients for clinical trials thereby creating better medicines that save lives. AI and Deep Analytics (AIDA) is a critical group in Data and Data…